FDA Brief

Company record

CSL Behring

1 FDA warning letter since 2023 and 0 recalls in the last 12 months.

Get an email the day FDA posts anything new about CSL Behring.

Warning letters

  1. CSL Behring

    FDA says CSL Behring's HIZENTRA TV ad overstates protection and plays down risks, misbranding the immune globulin biologic.

    Medium